Print

Neurognostics, Inc. Receives 510(k) Clearance For MindState® fDAD® Used For Acquisition Of fMRI Data 
10/19/2005 5:12:37 PM

Milwaukee, WI, February 1, 2005 Neurognostics, Inc., a Wisconsin based company developing clinical applications for functional Magnetic Resonance Imaging (fMRI), announced today that the Food and Drug Administration (FDA) has issued 510(k) approval for market clearance of MindState® functional Data Acquisition Device (fDAD®). fDAD® enables healthcare professionals to acquire fMRI data that may be used to track disease progression in patients afflicted by disorders of the central nervous system (CNS) and to test drug efficacy.
//-->